A bipartisan group of US House representatives is calling on the Food and Drug Administration (FDA) to address ongoing shortages of key chemotherapy drugs. In a letter written by Debbie Dingell (D-MI) and Tim Wahlberg (R-MI), lawmakers highlight the current shortages of cisplatin and carboplatin and point out they were either caused or exacerbated by a manufacturing hold last year on Intas Pharmaceuticals over quality issues.
According to Tyler Patchen, “The representatives are requesting an immediate briefing from the agency on the situation and want answers to several questions, including how the FDA is working with manufacturers to mitigate the shortage of the drugs, whether will there be additional shortages of other chemotherapy drugs, what can the FDA do to help increase production of the drugs and when it expects the shortage to start to lift.”
To read more, click here.
(Source: Endpoints News, May 25th, 2023)
